Skip to main content

View full-text article in PMC

. 2019 Jan 5;9(4):794–808. doi: 10.1016/j.apsb.2019.01.001

Table 5.

Antiproliferative activity of compounds 15s, 15u and 15y.

Cell line	Cell type	IC₅₀ (μmol/L)^a
		15s	15u	15y
OCI-AML3	Leukemia	2.50±0.54	1.79±0.14	4.72±1.11
K562	Leukemia	7.02±1.01	1.30±0.36	7.24±0.93
THP-1	Leukemia	1.14±0.25	0.45±0.11	2.52±0.82
U937	Leukemia	2.31±0.33	1.22±0.31	3.23±0.28
Raji	Lymphoma	3.02±0.95	1.40±0.49	3.32±0.75

^a

Cell lines were treated with compounds for 6 days. Data are expressed as the mean±SD of three independent experiments (n = 3).